|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
IL-4 and IL-13 are key cytokines in driving type 2 inflammation, a dominant and largely eosinophilic inflammatory pathway in asthma.
|
31728838 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Discovered DMRs annotated to genes implicated in allergic asthma, Th2 activation and eosinophilia (EPX, IL4, IL13) and genes previously associated with asthma and IgE in EWAS of blood (ACOT7, SLC25A25).
|
31300640 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings coupled with the known insensitivity of CD8<sup>+</sup> T cells to corticosteroids suggests that activation of the IL-4-HIF-1α-IL-13 axis might play a role in the development of steroid-refractory asthma.
|
30660639 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
MC-released preformed mediators including chymase, tryptase, and histamine and de novo synthesized mediators such as PGD2, LTC4, and LTE4 in addition of cytokines mainly TGFβ1, TSLP, IL-33, IL-4, and IL-13 participate in pathogenesis of asthma.
|
30506113 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Interleukin-13 (IL-13) drives symptoms in asthma with high levels of T-helper type 2 cells (T<sub>h</sub>2-cells).
|
31262043 |
2019 |
|
Asthma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Sputum IL-4, IL-5 and IL-13 protein levels did not correlate with gene expression.T2-high severe asthma can be predicted to some extent from raised levels of <i>F</i><sub>eNO</sub>, blood and sputum eosinophil counts, but serum IgE or serum periostin were poor predictors.
|
30578390 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Androgens, via AR, blunted TNFα or IL-13-induced enhancement of ASM [Ca<sup>2+</sup>]<sub>i</sub> in both males and females, with retained efficacy in asthmatics.
|
31299143 |
2019 |
|
Asthma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The A/A genotype frequency and A allele frequency of Arg130Gln locus in IL-13 in the asthma group were obviously higher than those in the control group (54.1 vs. 17.2%, OR=6.29; 67.6 vs. 39.7%, OR=3.17, P<0.05).
|
30680016 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Although these pathognomonic features are mainly mediated by antigen-specific Th2 cells and their cytokines, such as IL-4, IL-5, and IL-13, recent studies have revealed that other inflammatory cells, including Th17 cells and innate lymphoid cells (ILCs), also play a critical role in the pathogenesis of asthma.
|
30424940 |
2019 |
|
Asthma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Also, to correlate their expression levels to degree of severity of asthma as well as to IL-13 level and lung function parameters.
|
30981701 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
T helper 2 (Th2) lymphocytes and associated interleukin (IL) 4 and IL-13 play crucial roles in asthma pathogenesis.
|
31678897 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Recently, new biologics targeting interleukin (IL)-5, IL-5 receptor and IL-4/IL-13, which are all cytokines involved in so-called type 2 airway inflammation, were approved for severe asthma.
|
31229937 |
2019 |
|
Asthma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Dysregulated expression of IL-13 receptor subunits in the airways of asthmatics may thus contribute to the epithelial barrier dysfunction observed in asthma.-Yang, S. J., Allahverdian, S., Saunders, A. D. R., Liu, E., Dorscheid, D. R. IL-13 signaling through IL-13 receptor α2 mediates airway epithelial wound repair.
|
30481486 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our study suggests that anti-IL-13 monoclonal antibodies could improve the management of uncontrolled asthma.
|
30703143 |
2019 |
|
Asthma
|
0.700 |
Biomarker
|
disease |
BEFREE |
After knocking down the lung tissue of mice, the IL-4, IL-5 and IL-13 concentrations in broncho alveolar lavage fluid of asthmatic mice were significantly decreased, and the activation of JNK1/2-MMP-9 pathway was inhibited in mouse lung tissue.
|
31255288 |
2019 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Development of antagonistic antibody (Ab) against interleukin-4 receptor alpha (IL-4Rα) subunit of IL-4/IL-13 receptors is a promising therapeutic strategy for T helper 2 (T<sub>H</sub>2)-mediated allergic diseases such as asthma and atopic dermatitis.
|
31123339 |
2019 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Notably, SCCAs are induced by IL-4 and IL-13, vital Th2 cytokines that play important roles in AD etiology.
|
31378660 |
2019 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a monoclonal antibody blocking the action of IL-4 and IL-13 effectively reduces the symptoms of AD and itch.
|
31505056 |
2019 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
The overlap between the IL-13-stimulated epithelial cell transcriptome and the respective disease transcriptome was 22, 9, and 5% in EoE, AD, and AA, respectively, indicating a greater involvement of the IL-13 pathway in EoE than AA (<i>p</i> = 0.0007) or AD (<i>p</i> = 0.02).
|
31824894 |
2019 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Decreased levels of IFN-γ (Th1) and IL-17 (Th17), IL-4 and IL-13 (Th2) were detected in T cells and the skin tissue from the MSC-Ex treated AD mice.
|
31036853 |
2019 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dupilumab (a monoclonal antibody blocking the shared receptor component for IL-4 and IL-13) is approved for inadequately controlled moderate-to-severe AD and for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma.
|
31066001 |
2019 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively).
|
30981576 |
2019 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
In acute lesions of AD, the T-helper type 2 cells produce interleukin (IL) 4, IL-13, and IL-31, which may potentiate barrier dysfunction and contribute to pruritus.
|
31690388 |
2019 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Biologics targeting IL-13, such as the anti-IL-4Rα antibody dupilumab and the anti-IL-13 antibody tralokinumab, successfully improve AD lesions and further highlight the importance of IL-13 in the pathogenesis of AD.
|
31509236 |
2019 |
|
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Recently, cases of AA healing during treatment with anti-IL4/IL13 monoclonal antibody dupilumab (D) for AD were reported.
|
31306557 |
2019 |